Posted by Dr.Prahallad Panda on April 30, 2010
This link;”http://www.medpagetoday.com/MeetingCoverage/AHA/17058″, is all about the warning of FDA in concomitant use of some proton pump inhibitors (PPI) with clopidogrel; a blood thinning agent usually prescribed after stent placements and other cases of coronary artery disease treatment. It has been seen by the researchers that pantaprazole a PPI prescribed to reduce adverse effect of aspirin, which is also co-prescribed along with clopidogrel may interfere with the action of clopidogrel, adversely affecting the task of blood thinning.
| The risk of rehospitalization for myocardial infarction (MI) almost doubled in patients treated with both a proton pump inhibitor (PPI) and clopidogrel (Plavix) after acute MI or coronary stent deployment, data from a retrospective cohort study showed.
|
PPIs are frequently used to reduce the risk of gastrointestinal bleeding in patients treated with clopidogrel. However, a growing volume of evidence has suggested that PPIs might reduce clopidogrel’s efficacy, the authors wrote. |
In one recent study, patients treated with omeprazole (Prilosec) in addition to aspirin and clopidogrel had a significantly higher platelet reactivity index score after seven days of treatment than patients who didn’t get the PPI (J Am Coll Cardiol 2008; 51: 256-60). |
However, a subgroup analysis of a large clinical trial showed no increased risk of adverse events in patients who received clopidogrel with or without a PPI (Circulation 2008; 118(suppl 2): Abstract 3999). |
|
|
This entry was posted on April 30, 2010 at 6:59 am and is filed under Uncategorized.
.
You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.